Mesalmin Klysmen

Mesalazine, the active ingredient in Mesalmin Klysmen, is an aminosalicylate presented as an unspecified strength/rectal formulation for rectal use. It is used to treat inflammatory bowel conditions such as ulcerative colitis and Crohn's disease involving the colon.

GNH USA supplies Mesalmin Klysmen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalmin Klysmen, a mesalazine‑based aminosalicylate, is employed in the management of inflammatory bowel disease.

Ulcerative colitis: reduces mucosal inflammation and helps induce and maintain remission in patients with active disease. Crohn's disease (colonic involvement): controls colonic inflammation and supports maintenance of remission in affected individuals.

Mesalmin Klysmen may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rectal irritation or burning sensation - Abdominal pain or cramping - Nausea

Serious or Rare Side Effects: - Severe allergic reaction (rash, swelling, anaphylaxis) - Blood in stool or gastrointestinal bleeding - Significant liver enzyme elevation or hepatitis

Before initiating Mesalmin Klysmen, several precautionary measures should be considered to ensure safe use.

Assess disease severity: confirm active colonic inflammation before therapy. Monitor renal function: periodic serum creatinine and eGFR assessments are recommended. Monitor hepatic function: check liver enzymes regularly during treatment. Avoid concurrent NSAID use: combined therapy may increase risk of renal impairment. Check for hypersensitivity: discontinue if signs of allergic reaction appear. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mesalmin Klysmen can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Other 5‑ASA agents (e.g., sulfasalazine, olsalazine): additive toxicity. - Live vaccines: reduced efficacy and potential infection risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate renal dysfunction. - Diuretics: combined use can affect renal clearance of mesalazine. - ACE inhibitors or ARBs: monitor renal function when used together.